11 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 11, Recruiting 2, Terminated 2, Active not recruiting 1 |
Follow Dendreon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Sipuleucel-T Injection - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Dendreon | 400 | 2023-10-02 | 2025-08-27 |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2023-02-14 | 2026-09-15 |
| Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Radium-223, Sipuleucel-T - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 | 2016-02-22 | 2021-07-08 |
| Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer SipT Treatment, Ipilimumab - Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 50 | 2014-04-22 | 2021-08-18 |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer sipuleucel-T, enzalutamide - Metastatic Prostate Cancer | Phase 2 | Completed | Dendreon | 52 | 2013-09-01 | 2018-10-24 |
| Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer sipuleucel-T, DNA Vaccine - Prostate Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 18 | 2013-05-20 | 2021-06-18 |
| Sipuleucel-T Manufacturing Demonstration Study sipuleucel-T - Cancer of Prostate, Cancer of the Prostate | Phase 2 | Completed | Dendreon | 47 | 2012-06-01 | 2015-12-09 |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer sipuleucel-T, abiraterone acetate - Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer | Phase 2 | Completed | Dendreon | 69 | 2011-12-01 | 2019-03-19 |
| Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer sipuleucel-T - Prostate Cancer | Phase 2 | Terminated | Dendreon | 8 | 2011-12-01 | 2017-06-05 |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer sipuleucel-T, leuprolide acetate - Prostatic Neoplasm, Prostate Cancer | Phase 2 | Completed | Dendreon | 68 | 2011-09-01 | 2017-05-30 |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma DN24-02, Standard of Care - Urothelial Carcinoma | Phase 2 | Terminated | Dendreon | 142 | 2011-06-01 | 2017-05-25 |
| Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer sipuleucel-T - Prostate Cancer | Phase 2 | Completed | Dendreon | 104 | 2009-10-01 | 2017-05-23 |
| To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen sipuleucel-T - Prostate Cancer | Phase 2 | Completed | Dendreon | 122 | 2008-10-01 | 2017-05-23 |
| Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer Sipuleucel-T with Booster, Sipuleucel-T without Booster - Prostate Cancer | Phase 2 | Completed | Dendreon | 42 | 2008-07-01 | 2015-05-04 |
| Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) APC8015F - Metastatic Androgen Independent Prostate Cancer | Phase 2 | Completed | Dendreon | 113 | 2004-04-01 | 2023-11-29 |
Prostatic Neoplasms (12) · Neoplasms (3) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Genital Neoplasms, Male (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1)
sipuleucel-T (14) · enzalutamide (2) · Abiraterone Acetate (1) · Immunization, Secondary (1) · Ipilimumab (1) · Leuprolide (1) · Radium-223 (1) · Standard of Care (1) · Vaccines, DNA (1) · abiraterone (1) · apalutamide (1) · luprolide acetate gel depot (1) · radium Ra 223 dichloride (1) · regramostim (1) · testosterone 17 beta-cypionate (1)
United States (15) · Austria (1) · Canada (1) · France (1) · Netherlands (1) · United Kingdom (1)
Robert Israel, MD (6) · Andrew Stubbs, PhD (1) · Andy Sandler, MD (1) · Benjamin Lowentritt, MD (1) · Bruce Brown, MD (1) · Douglas McNeel, M.D., PhD (1) · Emmanuel Antonarakis, MD (1) · Jingsong Zhang, MD, PhD (1) · Joseph W Kim, MD (1) · Lawrence Fong, MD (1) · Nadeem Sheikh, PhD (1) · Padmanee Sharma, MD (1) · Paul Schellhammer, MD (1)
PMID 37058234, PMID 27216195, PMID 29534736, PMID 33451978, PMID 33986125, PMID 35027313